Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled (Part 1) or Active-controlled (Part 2) Trial of SABER® -Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy (PERSIST)

NCT02574520 is registered in ClinicalTrials.gov with Durect as lead sponsor.

NCT NCT02574520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02574520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled (Part 1) or Active-controlled (Part 2) Trial of SABER® -Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy (PERSIST)
Lead sponsor
Durect
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
August 31, 2017
Enrollment
399 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

post operative pain